The authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.
Niying Li, PhD, MSc
Advertisement
Articles by Niying Li, PhD, MSc
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
AI Chatbots Score Below 28% on Colorectal Cancer Questions
2
5 Notable FDA Approvals From the First Half of 2026
3
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
4
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
5